目的 二十五味余甘子丸聯(lián)合福辛普利鈉治療原發(fā)性高血壓的臨床效果。方法 選擇2017年2月—2019年3月在洪湖市中醫(yī)醫(yī)院治療的原發(fā)性高血壓患者131例，隨機(jī)分為對(duì)照組（65例）和治療組（66例）。對(duì)照組晨起口服福辛普利鈉片，1片/次，1次/d。治療組在對(duì)照組基礎(chǔ)上口服二十五味余甘子丸，3丸/次，2次/d。兩組患者均治療8周。觀察兩組患者臨床療效，同時(shí)比較治療前后兩組患者血壓水平，以及血清超敏C反應(yīng)蛋白（hs-CRP）、腫瘤壞死因子-α（TNF-α）和白細(xì)胞介素-6（IL-6）水平。結(jié)果 治療后，對(duì)照組臨床有效率為75.38%，顯著低于治療組的92.42%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組舒張壓（DBP）、收縮壓（SBP）均顯著降低（P<0.05），且治療組血壓水平明顯低于對(duì)照組（P<0.05）。治療后，兩組hs-CRP、TNF-α和IL-6水平均顯著降低（P<0.05），且治療組明顯比對(duì)照組低（P<0.05）。結(jié)論 二十五味余甘子丸聯(lián)合福辛普利鈉治療原發(fā)性高血壓可明顯降低患者舒張壓、收縮壓，具有較好的臨床療效，安全可靠。

Objective To analyze the clinical effect of Ershiwuwei Yuganzi Pills combined with fosinopril sodium in treatment of essential hypertension. Methods Patients (131 cases) with essential hypertension in Honghu Hospital of TCM from February 2017 to March 2019 were randomly divided into control (65 cases) and treatment (66 cases) groups. Patients in the control group were po administered with Fosinopril Sodium Tablets in the morning, 1 tablet/time, once daily. Patients in the treatment group were po administered with Ershiwuwei Yuganzi Pills on the basis of the control group, 3 pills/time, twice daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacy was evaluated, and the blood pressure level, and the serum level of hs-CRP, TNF-α and IL-6 in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 75.38%, which was significantly lower than 92.42% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the level of DBP and SBP in two groups was significantly decreased (P<0.05), and the blood pressure level in the treatment group was significantly lower than that in the control group (P<0.05). After treatment, the serum level of hs-CRP, TNF-α and IL-6 in two groups was significantly decreased (P<0.05), and which in the treatment group was significantly lower than that in the control group (P<0.05). Conclusion Ershiwuwei Yuganzi Pills combined with fosinopril sodium in treatment of essential hypertension can significantly reduce the DBP、SBP, which has good clinical efficacy, safety and reliability.

R972